semaglutide
Brand: RYBELSUS
Quick answer
semaglutide (RYBELSUS), is a pharmaceutical active ingredient, with approved status in the US.
Key facts
- INN
- semaglutide
- Brand
- RYBELSUS
- Route
- SOLUTION
- Formulation
- SOLUTION
Related news
Novo Nordisk Reports Record Q1 Revenue Driven by Wegovy and Ozempic Demand
Novo Nordisk has reported record Q1 revenue driven by strong demand for Wegovy and Ozempic. This article analyzes the implications for investors and the competitive landscape.
Novo Nordisk's Oral Ozempic Becomes First FDA-Approved Pill GLP-1 for Type 2 Diabetes with Cardiovascular Protection
Novo Nordisk's oral Ozempic pill receives FDA approval as the first oral GLP-1 medication for type 2 diabetes with cardiovascular risk reduction benefits.
GLP-1 Eating Disorder Risk: What You Need to Know
Recent concerns about GLP-1 receptor agonists like semaglutide highlight potential eating disorder risks. This article reviews current evidence, FDA stance, and safety considerations.
Novo Nordisk's Oral Semaglutide Shows Promise as First GLP-1 Therapy for Children with Type 2 Diabetes
Novo Nordisk's PIONEER TEENS trial demonstrates oral semaglutide significantly reduces blood sugar in children with type 2 diabetes, paving way for regulatory filings.
FDA Approves Semaglutide Trial Update for Obesity Treatment
The FDA has approved an update to the Semaglutide trial, enhancing its potential as a groundbreaking treatment for obesity.
FDA Approves Higher-Dose Wegovy 7.2mg for Weight Loss Under Priority Review Program
Novo Nordisk's Wegovy receives FDA approval for 7.2mg dose under National Priority Voucher Program, expanding treatment options for adult obesity patients.
Frequently asked questions
What is semaglutide?
semaglutide (RYBELSUS), is a pharmaceutical active ingredient, with approved status in the US.
What is the brand name for semaglutide?
RYBELSUS is a marketed brand name for semaglutide. Check FDA Drugs@FDA for the current US label holder.